Methods related to surgery
First Claim
1. A method for accelerating the rate of healing of a surgically created anastomosis in a treated patient compared to the rate of healing in an untreated patient, the method comprising the step of administering by injection directly to the anastomosis at the time the anastomosis is surgically created between 0.1-to-1000 μ
- L per square centimeter of applied area a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS) or pooled ACCS wherein the ACCS or pooled ACCS contains physiologic concentrations of VEGF, TGFβ
2, Angiogenin, PDGF, TIMP-1 and TIMP-2, and wherein the physiologic concentration is about 5.0-16 ng/mL for VEGF, about 3.5-4.5 ng/mL for Angiogenin, about 100-165 pg/mL for PDGF, about 2.5-2.7 ng/mL for TGFβ
2, about 0.68 μ
g/mL for TIMP-1 and about 1.04 μ
g/mL for TIMP-2.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.
43 Citations
3 Claims
-
1. A method for accelerating the rate of healing of a surgically created anastomosis in a treated patient compared to the rate of healing in an untreated patient, the method comprising the step of administering by injection directly to the anastomosis at the time the anastomosis is surgically created between 0.1-to-1000 μ
- L per square centimeter of applied area a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS) or pooled ACCS wherein the ACCS or pooled ACCS contains physiologic concentrations of VEGF, TGFβ
2, Angiogenin, PDGF, TIMP-1 and TIMP-2, and wherein the physiologic concentration is about 5.0-16 ng/mL for VEGF, about 3.5-4.5 ng/mL for Angiogenin, about 100-165 pg/mL for PDGF, about 2.5-2.7 ng/mL for TGFβ
2, about 0.68 μ
g/mL for TIMP-1 and about 1.04 μ
g/mL for TIMP-2. - View Dependent Claims (2, 3)
- L per square centimeter of applied area a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS) or pooled ACCS wherein the ACCS or pooled ACCS contains physiologic concentrations of VEGF, TGFβ
Specification
-
- Resources
-
Current AssigneeStemnion, Inc.
-
Original AssigneeStemnion, Inc.
-
InventorsPalladino, Linda O., Clarke, Diana L., Marshall, Vivienne S., Smith, Charlotte A., Robson, Martin C.
-
Primary Examiner(s)DRISCOLL, LORA E BARNHART
-
Application NumberUS12/217,259Publication NumberTime in Patent Office1,378 DaysField of SearchNoneUS Class Current435/405CPC Class CodesA61K 35/50 Placenta; Placental stem ce...A61P 43/00 Drugs for specific purposes...
